Drug Combination Details
| General Information of the Combination (ID: C63262) | |||||
|---|---|---|---|---|---|
| Name | Magnolol NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Sarcopenia
[ICD-11: FB32]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | ||
| CT26 | CVCL_7254 | Mouse colon adenocarcinoma | Mus musculus | |||
| Experimental
Result(s) |
Magnolol attenuates cisplatin-induced muscle wasting by M2c macrophage activation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation. Front Immunol. 2020 Feb 7;11:77. | |||
